ES2147309T3 - Composiciones de ondansetron liofilizadas. - Google Patents

Composiciones de ondansetron liofilizadas.

Info

Publication number
ES2147309T3
ES2147309T3 ES95940208T ES95940208T ES2147309T3 ES 2147309 T3 ES2147309 T3 ES 2147309T3 ES 95940208 T ES95940208 T ES 95940208T ES 95940208 T ES95940208 T ES 95940208T ES 2147309 T3 ES2147309 T3 ES 2147309T3
Authority
ES
Spain
Prior art keywords
compositions
ondansetron
lyophilized
hydroxitriptamine
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95940208T
Other languages
English (en)
Inventor
Ian Keith Winterborn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10764757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2147309(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Application granted granted Critical
Publication of ES2147309T3 publication Critical patent/ES2147309T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Fertilizers (AREA)

Abstract

LA INVENCION SE REFIERE A UNA FORMA DE DOSIFICACION SECADA POR CONGELACION PARA LA ADMINISTRACION ORAL CAPAZ DE SER RAPIDAMENTE DESINTEGRADA EN LA BOCA QUE INCLUYE ONDANSETRON EN LA FORMA DE SU BASE LIBRE O UN SOLVATO ACEPTABLE FARMACEUTICAMENTE DEL MISMO Y UNO O MAS EXCIPIENTES ACEPTABLES FARMACEUTICAMENTE. TAMBIEN SE DESCRIBEN METODOS PARA LA ELABORACION DE DICHAS COMPOSICIONES Y PARA SU USO EN EL TRATAMIENTO DE AFECCIONES INFLUIDAS POR LA ACCION DE 5-HIDROXITRIPTAMINA (5HT) EN LOS RECEPTORES 5HT{SUB,3}.
ES95940208T 1994-11-22 1995-11-20 Composiciones de ondansetron liofilizadas. Expired - Lifetime ES2147309T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9423511A GB9423511D0 (en) 1994-11-22 1994-11-22 Compositions

Publications (1)

Publication Number Publication Date
ES2147309T3 true ES2147309T3 (es) 2000-09-01

Family

ID=10764757

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95940208T Expired - Lifetime ES2147309T3 (es) 1994-11-22 1995-11-20 Composiciones de ondansetron liofilizadas.

Country Status (30)

Country Link
US (2) US5955488A (es)
EP (1) EP0793495B1 (es)
JP (1) JP3001264B2 (es)
KR (1) KR970706814A (es)
CN (1) CN1080118C (es)
AT (1) ATE193444T1 (es)
AU (1) AU704160B2 (es)
BE (1) BE1010250A3 (es)
BR (1) BR9509808A (es)
CY (1) CY2166B1 (es)
CZ (1) CZ285250B6 (es)
DE (1) DE69517332T2 (es)
DK (1) DK0793495T3 (es)
ES (1) ES2147309T3 (es)
FI (1) FI119355B (es)
FR (1) FR2727016B1 (es)
GB (2) GB9423511D0 (es)
GR (1) GR3033937T3 (es)
HU (1) HU226891B1 (es)
IL (1) IL116084A (es)
IT (1) IT1282352B1 (es)
MX (1) MX9703735A (es)
NO (1) NO306893B1 (es)
NZ (1) NZ296982A (es)
PL (1) PL181179B1 (es)
PT (1) PT793495E (es)
RU (1) RU2159614C2 (es)
TW (1) TW398976B (es)
WO (1) WO1996015785A1 (es)
ZA (1) ZA959821B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976577A (en) * 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
EP1036561A1 (en) * 1997-10-01 2000-09-20 Flemington Pharmaceutical Corporation Buccal, non-polar spray
US6630006B2 (en) * 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
EP1246668B1 (en) * 1999-12-01 2005-11-30 Natco Pharma Limited An rapid acting freeze dired oral pharmaceutical composition for treating migraine
RU2162847C1 (ru) * 2000-07-14 2001-02-10 ООО с иностранными инвестициями "Редди-Биомед лимитед" Способ получения ондансетрона и его фармацевтически приемлемых солей
US20020107275A1 (en) * 2000-10-30 2002-08-08 Ramy Lidor-Hadas Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
CN1665823A (zh) * 2002-04-29 2005-09-07 特瓦药厂有限公司 制备1,2,3,9－四氢－9－甲基－3－[(2－甲基－1h－咪唑－1－基)甲基]－4h－咔唑－4－酮的方法
KR20040104677A (ko) * 2002-04-30 2004-12-10 비오갈 기오기스제르갸르 알티. 신규의 온단세트론 결정 형태, 그 제조 방법, 그 신규의결정 형태를 함유하는 약학 조성물 및 이들을 이용한구역질 치료 방법
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
CA2505990C (en) * 2002-11-15 2009-05-19 Helsinn Healthcare S.A. Palonosetron for the treatment of chemotherapy-induced emesis
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
MY143789A (en) 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
IL174758A (en) 2003-10-10 2012-09-24 Synthon Bv Crystalline form of montelukast, pharmaceutical composition comprising it, process for the preparation thereof and uses thereof as a medicament
EP1709053B1 (en) 2004-01-27 2011-04-06 Synthon B.V. Stable salts of olanzapine
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
US7829716B2 (en) * 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
US7501517B2 (en) * 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
EP1758937B1 (en) * 2004-05-24 2009-09-02 Genvault Corporation Stable protein storage and stable nucleic acid storage in recoverable form
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
EP1919923A1 (en) * 2005-08-17 2008-05-14 Synthon B.V. A process for making olanzapine form i
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
AR057909A1 (es) * 2005-11-18 2007-12-26 Synthon Bv Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
EP1996552A1 (en) * 2006-03-17 2008-12-03 Synthon B.V. Montelukast amantadine salt
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
US20080138409A1 (en) * 2006-09-29 2008-06-12 Osinga Niels J Olanzapine pharmaceutical composition
EP2813144A1 (en) 2006-10-09 2014-12-17 Charleston Laboratories, Inc. Analgesic compositions comprising an antihistamine
NZ576237A (en) * 2006-10-24 2011-12-22 Helsinn Healthcare Sa Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
RU2363463C1 (ru) * 2007-11-14 2009-08-10 Федеральное государственное унитарное предприятие Научно-производственный центр "Фармзащита" Федерального медико-биологического агентства Лекарственное средство
EP3090743A1 (en) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
WO2009130056A1 (en) * 2008-04-25 2009-10-29 Synthon B.V. Process for making montelukast intermediates
EP2253316B1 (en) * 2009-05-20 2013-08-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin 5-HT3 receptor antagonists for use in the treatment or prevention of an inner ear pathology with vestibular deficits
JP5955767B2 (ja) * 2009-05-20 2016-07-20 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 損傷性前庭障害の処置における使用のためのセロトニン５−ｈｔ３受容体拮抗薬
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
US10172833B2 (en) 2015-08-11 2019-01-08 Insys Development Company, Inc. Sublingual ondansetron spray
EP3423041A4 (en) 2016-03-04 2019-09-11 Charleston Laboratories, Inc. PHARMACEUTICAL COMPOSITIONS
SI3442537T1 (sl) 2016-04-14 2024-05-31 Sensorion (+)-azasetron za uporabo pri zdravljenju ušesnih obolenj

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0084705B1 (en) * 1981-12-11 1987-01-14 JOHN WYETH & BROTHER LIMITED Process for preparing solid shaped articles
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
GB8917556D0 (en) * 1989-08-01 1989-09-13 Glaxo Group Ltd Medicaments
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
EP0450757A3 (en) * 1990-02-22 1993-09-15 Glaxo Group Limited Use of 5-hydroxytryptamine-antagonists in the treatment of mental disorders originating in childhood
US5046618A (en) * 1990-11-19 1991-09-10 R. P. Scherer Corporation Child-resistant blister pack

Also Published As

Publication number Publication date
FI972167A0 (fi) 1997-05-21
US6063802A (en) 2000-05-16
GB2295318B (en) 1998-10-28
ITRM950762A0 (es) 1995-11-20
HK1009591A1 (en) 1999-06-04
PL320295A1 (en) 1997-09-15
TW398976B (en) 2000-07-21
CZ154997A3 (en) 1997-10-15
HU226891B1 (en) 2010-01-28
GB9523667D0 (en) 1996-01-24
RU2159614C2 (ru) 2000-11-27
IT1282352B1 (it) 1998-03-20
PT793495E (pt) 2000-10-31
IL116084A0 (en) 1996-01-31
JPH10508864A (ja) 1998-09-02
GR3033937T3 (en) 2000-11-30
DK0793495T3 (da) 2000-10-09
WO1996015785A1 (en) 1996-05-30
BR9509808A (pt) 1997-10-21
PL181179B1 (pl) 2001-06-29
AU704160B2 (en) 1999-04-15
EP0793495B1 (en) 2000-05-31
CY2166B1 (en) 2002-08-23
HUT77886A (hu) 1998-09-28
FR2727016A1 (fr) 1996-05-24
FR2727016B1 (fr) 1998-04-03
ATE193444T1 (de) 2000-06-15
DE69517332T2 (de) 2000-11-30
BE1010250A3 (fr) 1998-04-07
GB2295318A (en) 1996-05-29
CN1080118C (zh) 2002-03-06
ZA959821B (en) 1996-07-31
US5955488A (en) 1999-09-21
JP3001264B2 (ja) 2000-01-24
KR970706814A (ko) 1997-12-01
FI972167L (fi) 1997-05-21
NO972325L (no) 1997-05-22
NO972325D0 (no) 1997-05-21
EP0793495A1 (en) 1997-09-10
NO306893B1 (no) 2000-01-10
FI119355B (fi) 2008-10-31
AU4173996A (en) 1996-06-17
MX9703735A (es) 1998-07-31
IL116084A (en) 2000-01-31
NZ296982A (en) 1998-06-26
CZ285250B6 (cs) 1999-06-16
ITRM950762A1 (it) 1997-05-20
DE69517332D1 (de) 2000-07-06
GB9423511D0 (en) 1995-01-11
CN1171741A (zh) 1998-01-28

Similar Documents

Publication Publication Date Title
ES2147309T3 (es) Composiciones de ondansetron liofilizadas.
ES2151083T3 (es) Composiciones orales que contienen ondansetron.
AR013506A1 (es) Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida
CO5680109A1 (es) Compuestos para el tratamiento de la disfuncion sexual femenina
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
ES2086546T3 (es) Productos de cemento de alta duracion conteniendo cenizas siliceas.
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
AR028810A1 (es) Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion
CY1107874T1 (el) Φαρμακευτικh σyνθεση επιβραδυνoμενης αποδεσμευσης φλουβαστατiνης
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
PA8562101A1 (es) Metodos para granulacion humeda de azitromicina
PE68899A1 (es) Composicion que contiene paracetamol
PE20020329A1 (es) DERIVADOS DE 10-ARIL-11H-BENZO[b]FLUORENO Y ANALOGOS COMO COMPUESTOS ESTROGENICOS
ES2113533T3 (es) Composiciones farmaceuticas de alquilsulfonamidas agonistas de 5-ht1 para administracion rectal.
AR035006A1 (es) Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento.
AR011697A1 (es) Composiciones farmaceuticas, uso de lamivudina en la manufactura de tales composiciones farmaceuticas.
SE0001916D0 (sv) Novel formulation
ES2136198T3 (es) Composiciones rectales que contienen odansetron en forma de su base libre.
AR017215A1 (es) Composiciones que contienen generadores de oxido nitrico y uso de dichos generadores para la preparacion de un medicamento util para el tratamiento detrastornos de ojo seco
CA2205600A1 (en) Freeze-dried ondansetron compositions
AR036257A1 (es) Sulfamatos de 2-alcoxiestradiol de accion antitumoral
PA8508401A1 (es) Composiciones de valdecoxib
ES2133052A1 (es) Nuevas formulaciones farmaceuticas liquidas para la via oral.
ES2191106T3 (es) Uso de ondansetron en la fabricacion de un medicamento para el tratamiento del temblor.
ES2186812T3 (es) Tratamiento oral o intramuscular del cancer pancreatico con s-camptotecina insoluble en agua de la forma de anillo de lactona cerrado.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 793495

Country of ref document: ES